Zimmer Biomet Holdings, Inc. announced a leadership restructuring effective September 8, 2026. Kevin Thornal, Group President of Global Businesses and the Americas, is departing on September 30, 2026, receiving severance equal to twelve months of base salary plus target bonus and COBRA premiums. Gary Campbell was promoted to President, Americas; Brian Hatcher to President for Recon, S.E.T., CMFT, Neuro and Biosurgery; and Bradley Kessler to President, Americas – Robotics, Technology and Data. The company reiterated its full-year 2026 financial outlook previously provided on August 5, 2026. Zimmer Biomet is a global medical technology leader specializing in orthopedic implants, digital solutions, and robotic technologies.

Zimmer Biomet Holdings reported second quarter 2026 net sales of $2.177 billion, a 4.8% increase over the prior year period. Diluted earnings per share rose 33.8% to $1.03, while adjusted diluted EPS remained consistent at $2.07. The company generated $447.9 million in operating cash flow and $308.3 million in free cash flow. Management raised full-year 2026 guidance, projecting reported revenue growth of 3.9% to 4.9% and adjusted diluted EPS of $8.47 to $8.59. Additionally, the company announced an increase to share repurchase expectations of up to $1 billion for fiscal year 2026 and named Chintan Desai president of its Asia Pacific Region. Zimmer Biomet operates in the medical technology industry, designing and manufacturing orthopedic products and surgical solutions.

Zimmer Biomet Holdings, Inc. entered into two new unsecured revolving credit agreements on June 26, 2026. The first is a $1.5 billion five-year facility maturing June 26, 2031, which includes an uncommitted $750 million incremental feature. The second is a $1.25 billion 364-day facility maturing June 25, 2027. Both agreements, administered by JPMorgan Chase Bank, N.A., carry a consolidated indebtedness to EBITDA ratio covenant of 4.5 to 1.0, potentially increasing to 5.0 to 1.0 for certain acquisitions. These new facilities replaced existing 2025 credit agreements that had no outstanding principal balance. Zimmer Biomet is a medical technology company that manufactures orthopedic products.